Research study validates Neuroreader® for accurate and fast measurement of brain volumes

Research study validates Neuroreader® for accurate and fast measurement of brain volumes

Study, published in Journal of Alzheimer’s Disease, highlights software’s role in tracking key ‘vital sign’ for brain health.


A new neuroimaging software, Neuroreader®, was shown to be as accurate as traditional methods for detecting the slightest changes in brain volume, and does so in a fraction of the time, according to a research study published in the Journal of Alzheimer’s Disease this month. The research validates the software program that can be used for measuring hippocampal volume, a biomarker for detecting Alzheimer’s Disease.

The study, which was conducted earlier this year by a team of 10 researchers, neurologists, radiologists and other healthcare professionals, representing six different organizations, sought to test the accuracy and speed of the Neuroreader® software in detecting changes in brain volume on MRIs. Neuroreader®, a product of Denmark-based medical technology company Brainreader, is a U.S. Food and Drug Administration-cleared software program for assessment of clinical volume on brain MRIs.

Independently performed study in both Denmark and USA

Titled, “Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging,” the research was performed independently in Denmark and at the Medical College of Wisconsin, with both studies producing similar results. One of the study’s lead authors and the inventor of Neuroreader®, Dr. Jamila Ahdidan, conducted a study at her Brainreader labs, while Edgar A. DeYoe, PhD, a professor in the Department of Radiology at the Medical College of Wisconsin, replicated the study independently in his facility.

Research compared the results of 1.5 T and 3.0 T MRI scans processed by Neuroreader® with those which were traced manually by expert anatomists and radiologists. Prior to the onset of neuroimaging software, manual tracing has been the “gold standard” — the most accurate method — used among healthcare professionals.

Automated segmentation can be a vital tool for early diagnosis of Alzheimer’s disease

Measuring the level of spatial overlap between Neuroreader® and “gold standard” manual segmentation, Neuroreader® was on average more than 87% accurate in its agreement with the gold standard method, but could accomplish this task in a fraction of the time – in about 5 minutes per scan compared to 30 minutes for manual segmentation.

The study’s results indicate that neuroimaging software, because it allows radiologists to quickly detect subtle changes in brain volumes, can be a vital tool in the early diagnosis of Alzheimer’s and other degenerative brain diseases.

Neuroreader® adds value to any MRI scanner

“For more than 30 years, since the development of the Magnetic Resonance Imaging scanner, the MRI has been the go-to test equipment to find abnormalities in brain volume, which provides strong indication of brain trauma or disease,” said Dr. Oscar Lopez, of the University of Pittsburgh’s Department of Neurology. “Neuroreader® adds value to any MRI scanner by providing fast and accurate measurements of brain structure.”

David Merrill, a geriatric psychiatrist at UCLA said, “In applying Neuroreader® to my patients with memory loss what I find it most useful for is helping me understand which patients do not have Alzheimer’s. Many persons with psychiatric disorders but not Alzheimer’s have cognitive problems.”

Dr. Dale E. Bredesen, Professor of Neurology at UCLA and founding President and CEO of the Buck Institute for Research on Aging, said, “Regional brain volumes are critical, not only for identifying and differentiating neurodegenerative processes such as Alzheimer’s disease, but also for documenting successful therapeutic approaches.”

According to John L. Ulmer, MD, Director of Neuroradiology at the Medical College of Wisconsin, “People at risk for Alzheimer’s dementia need to know their hippocampal volumes as an important number – just as someone at risk for a heart attack would need to know their cholesterol count.”


Public release October 2015